SCYNEXIS, Inc. Net Fee Amt
SCYNEXIS, Inc. (SCYX) had Net Fee Amt of $1.15 thousand as of 2026-08-10, per its S-8 filed 2026-08-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-10
- 2026-08-10: Net Fee Amt $1.15K.
- 2026-05-01: Net Fee Amt $11.29K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-10 | $1.15K S-8 · filed 2026-08-10 |
| 2026-05-01 | $11.29K S-3 · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |